Characterization of the basement membrane in kidney renal clear cell carcinoma to guide clinical therapy

被引:7
作者
Xiong, Xi [1 ]
Chen, Chen [1 ]
Yang, Jun [2 ]
Ma, Li [3 ]
Wang, Xiong [3 ]
Zhang, Wei [2 ]
Yuan, Yuan [4 ]
Peng, Min [5 ]
Li, Lili [6 ]
Luo, Pengcheng [1 ]
机构
[1] Wuhan Univ Sci & Technol, Wuhan Hosp 3, Sch Med, Dept Urol, Wuhan, Peoples R China
[2] Wuhan Third Hosp, Dept Urol, Wuhan, Peoples R China
[3] Wuhan Third Hosp, Dept Pharm, Wuhan, Peoples R China
[4] Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Urol, Wuhan, Peoples R China
[5] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan, Peoples R China
[6] Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金;
关键词
kidney renal clear cell carcinoma; basement membrane; prognosis; tumor microenvironment; immunotherapy; CANCER;
D O I
10.3389/fonc.2022.1024956
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundRenal cell carcinoma (RCC) is the most common kidney cancer in adults. According to the histological features, it could be divided into several subtypes, of which the most common one is kidney renal clear cell carcinoma (KIRC), which contributed to more than 90% of cases for RCC and usually ends with a dismal outcome. Previous studies suggested that basement membrane genes (BMGs) play a pivotal role in tumor development. However, the significance and prognostic value of BMGs in KIRC still wrap in the mist. MethodsKIRC data were downloaded from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. A prognostic risk score (PRS) model based on BMGs was established using univariate and least absolute shrinkage and selection operator (LASSO) and the Cox regression analysis was performed for prognostic prediction. The Kaplan-Meier analysis, univariate Cox regression, multivariate Cox regression, receiver operating characteristic (ROC) curves, nomogram, and calibration curves were utilized to evaluate and validate the PRS model. All KIRC cases were divided into the high-risk score (HRS) group and the low-risk score (LRS) group according to the median risk scores. In addition, single-sample gene set enrichment analysis (ssGSEA), immune analysis, tumor microenvironment (TME) analysis, principal component analysis (PCA), and half-maximal inhibitory concentration (IC50) were also applied. Expression levels of BMGs were confirmed by qRT-PCR in both human renal cancer cell lines and tissues. ResultsWe established the BMGs-based prognostic model according to the following steps. Within the TCGA cohort, patients' prognosis of the HRS group was significantly worse than that of the LRS group, which was consistent with the analysis results of the GEO cohort. PCA patterns were significantly distinct for LRS and HRS groups and pathological features of the HRS group were more malignant compared with the LRS group. Correlation analysis of the PRS model and TME features, such as immune cell scores, stromal cell scores, and ESTIMATE values, revealed a higher immune infiltration in the HRS group compared with the LRS group. The chemotherapeutic response was also evaluated in KIRC treatment. It showed that the HRS group exhibited stronger chemoresistance to chemotherapeutics like FR-180204, GSK1904529A, KIN001-102, and YM201636. The therapeutic reactivity of the other 27 chemotherapeutic agents was summarized as well. Furthermore, the FREM2 level was measured in both human kidney tissues and associated cell lines, which suggested that lower FREM2 expression prompts a severer pathology and clinical ending. ConclusionsOur study showed that KIRC is associated with a unique BMG expression pattern. The risk scores related to the expression levels of 10 BMGs were assessed by survival status, TME, pathological features, and chemotherapeutic resistance. All results suggested that FREM2 could be a potential candidate for KIRC prognosis prediction. In this study, we established a valid model and presented new therapeutic targets for the KIRC prognosis prediction as well as the clinical treatment recommendation, and finally, facilitated precision tumor therapy for every single individual.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] m7G regulator-mediated molecular subtypes and tumor microenvironment in kidney renal clear cell carcinoma
    Chen, Mei
    Nie, Zhenyu
    Gao, Yuanhui
    Cao, Hui
    Zheng, Linlin
    Guo, Na
    Peng, Yanling
    Zhang, Shufang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy
    Meng, Jialin
    Jiang, Aimin
    Lu, Xiaofan
    Gu, Di
    Ge, Qintao
    Bai, Suwen
    Zhou, Yundong
    Zhou, Jun
    Hao, Zongyao
    Yan, Fangrong
    Wang, Linhui
    Wang, Haitao
    Du, Juan
    Liang, Chaozhao
    IMETA, 2023, 2 (04):
  • [43] Analyzing and Validating the Prognostic Value of a TNF-Related Signature in Kidney Renal Clear Cell Carcinoma
    Zhang, Wenhao
    Li, Changjiu
    Wu, Fanding
    Li, Ning
    Wang, Yuwei
    Hu, Yixuan
    Fang, Tiantian
    Yuan, Hui
    He, Huadong
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [44] Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment
    Ye, Yang
    Zeng, Song
    Hu, Xiaopeng
    APOPTOSIS, 2024, 29 (5-6) : 693 - 708
  • [45] Downregulation of PPA2 expression correlates with poor prognosis of kidney renal clear cell carcinoma
    Zhu, Wenbiao
    Jiang, Huiming
    Xie, Shoucheng
    Xiao, Huanqin
    Liu, Qinghua
    Chen, Nanhui
    Wan, Pei
    Lu, Shanming
    PEERJ, 2021, 9 (09):
  • [46] ZEB family is a prognostic biomarker and correlates with anoikis and immune infiltration in kidney renal clear cell carcinoma
    Lin, Sheng
    Chen, Qi
    Tan, Canliang
    Su, Manyi
    Min, Ling
    Ling, Lv
    Zhou, Junhao
    Zhu, Ting
    BMC MEDICAL GENOMICS, 2024, 17 (01)
  • [47] Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment
    Yang Ye
    Song Zeng
    Xiaopeng Hu
    Apoptosis, 2024, 29 : 693 - 708
  • [48] JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma
    Liang, Feiguo
    Liang, Hao
    Li, Zuwei
    Huang, Peiyuan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 86
  • [49] Comprehensive analysis reveals dual biological function roles of EpCAM in kidney renal clear cell carcinoma
    Chen, Mei
    Gao, Yuanhui
    Cao, Hui
    Wang, Zhenting
    Zhang, Shufang
    HELIYON, 2024, 10 (01)
  • [50] Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
    Comandone, Alessandro
    Vana, Federica
    Comandone, Tiziana
    Tucci, Marcello
    CANCERS, 2021, 13 (23)